Selected research
Industry Research
CD40 Ligand Industry Research Report 2026
Market perspective
The global CD40 Ligand market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for CD40 Ligand is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for CD40 Ligand is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for CD40 Ligand is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of CD40 Ligand include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global CD40 Ligand market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CD40 Ligand Market by Company
Biogen, Inc.
XL-protein GmbH
Targovax AS
MedImmune, LLC
Juno Therapeutics Inc.
ImmuNext, Inc.
eTheRNA Immunotherapies NV
Bristol-Myers Squibb Company
CD40 Ligand Segment by Type
ISF-35
MegaCD40L
MEDI-4920
LOAd-700
Others
CD40 Ligand Segment by Application
Hepatitis B
Ovarian Cancer
Liver Cancer
Bladder Cancer
Others
CD40 Ligand Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD40 Ligand market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CD40 Ligand and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD40 Ligand.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of CD40 Ligand manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of CD40 Ligand by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of CD40 Ligand in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ISF-35
- MegaCD40L
- MEDI-4920
- LOAd-700
- Others
Applications
- Hepatitis B
- Ovarian Cancer
- Liver Cancer
- Bladder Cancer
- Others
Companies covered
- Biogen, Inc.
- XL-protein GmbH
- Targovax AS
- MedImmune, LLC
- Juno Therapeutics Inc.
- ImmuNext, Inc.
- eTheRNA Immunotherapies NV
- Bristol-Myers Squibb Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global CD40 Ligand Market Size (2021-2032)
- 2.2.2 Global CD40 Ligand Sales (2021-2032)
- 2.2.3 Global CD40 Ligand Market Average Price (2021-2032)
- 2.3 CD40 Ligand by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ISF-35
- 2.3.3 MegaCD40L
- 2.3.4 MEDI-4920
- 2.3.5 LOAd-700
- 2.3.6 Others
- 2.4 CD40 Ligand by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hepatitis B
- 2.4.3 Ovarian Cancer
- 2.4.4 Liver Cancer
- 2.4.5 Bladder Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global CD40 Ligand Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global CD40 Ligand Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global CD40 Ligand Revenue of Manufacturers (2021-2026)
- 3.4 Global CD40 Ligand Average Price by Manufacturers (2021-2026)
- 3.5 Global CD40 Ligand Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of CD40 Ligand, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of CD40 Ligand, Product Type & Application
- 3.8 Global Manufacturers of CD40 Ligand, Established Date
- 3.9 Global CD40 Ligand Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biogen, Inc.
- 4.1.1 Biogen, Inc. Company Information
- 4.1.2 Biogen, Inc. Business Overview
- 4.1.3 Biogen, Inc. CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biogen, Inc. CD40 Ligand Product Portfolio
- 4.1.5 Biogen, Inc. Recent Developments
- 4.2 XL-protein GmbH
- 4.2.1 XL-protein GmbH Company Information
- 4.2.2 XL-protein GmbH Business Overview
- 4.2.3 XL-protein GmbH CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 XL-protein GmbH CD40 Ligand Product Portfolio
- 4.2.5 XL-protein GmbH Recent Developments
- 4.3 Targovax AS
- 4.3.1 Targovax AS Company Information
- 4.3.2 Targovax AS Business Overview
- 4.3.3 Targovax AS CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Targovax AS CD40 Ligand Product Portfolio
- 4.3.5 Targovax AS Recent Developments
- 4.4 MedImmune, LLC
- 4.4.1 MedImmune, LLC Company Information
- 4.4.2 MedImmune, LLC Business Overview
- 4.4.3 MedImmune, LLC CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MedImmune, LLC CD40 Ligand Product Portfolio
- 4.4.5 MedImmune, LLC Recent Developments
- 4.5 Juno Therapeutics Inc.
- 4.5.1 Juno Therapeutics Inc. Company Information
- 4.5.2 Juno Therapeutics Inc. Business Overview
- 4.5.3 Juno Therapeutics Inc. CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Juno Therapeutics Inc. CD40 Ligand Product Portfolio
- 4.5.5 Juno Therapeutics Inc. Recent Developments
- 4.6 ImmuNext, Inc.
- 4.6.1 ImmuNext, Inc. Company Information
- 4.6.2 ImmuNext, Inc. Business Overview
- 4.6.3 ImmuNext, Inc. CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ImmuNext, Inc. CD40 Ligand Product Portfolio
- 4.6.5 ImmuNext, Inc. Recent Developments
- 4.7 eTheRNA Immunotherapies NV
- 4.7.1 eTheRNA Immunotherapies NV Company Information
- 4.7.2 eTheRNA Immunotherapies NV Business Overview
- 4.7.3 eTheRNA Immunotherapies NV CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 eTheRNA Immunotherapies NV CD40 Ligand Product Portfolio
- 4.7.5 eTheRNA Immunotherapies NV Recent Developments
- 4.8 Bristol-Myers Squibb Company
- 4.8.1 Bristol-Myers Squibb Company Company Information
- 4.8.2 Bristol-Myers Squibb Company Business Overview
- 4.8.3 Bristol-Myers Squibb Company CD40 Ligand Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bristol-Myers Squibb Company CD40 Ligand Product Portfolio
- 4.8.5 Bristol-Myers Squibb Company Recent Developments
5 Global CD40 Ligand Market Scenario by Region
- 5.1 Global CD40 Ligand Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global CD40 Ligand Sales by Region: 2021-2032
- 5.2.1 Global CD40 Ligand Sales by Region: 2021-2026
- 5.2.2 Global CD40 Ligand Sales by Region: 2027-2032
- 5.3 Global CD40 Ligand Revenue by Region: 2021-2032
- 5.3.1 Global CD40 Ligand Revenue by Region: 2021-2026
- 5.3.2 Global CD40 Ligand Revenue by Region: 2027-2032
- 5.4 North America CD40 Ligand Market Facts & Figures by Country
- 5.4.1 North America CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America CD40 Ligand Sales by Country (2021-2032)
- 5.4.3 North America CD40 Ligand Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe CD40 Ligand Market Facts & Figures by Country
- 5.5.1 Europe CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe CD40 Ligand Sales by Country (2021-2032)
- 5.5.3 Europe CD40 Ligand Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific CD40 Ligand Market Facts & Figures by Country
- 5.6.1 Asia Pacific CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific CD40 Ligand Sales by Country (2021-2032)
- 5.6.3 Asia Pacific CD40 Ligand Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America CD40 Ligand Market Facts & Figures by Country
- 5.7.1 South America CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America CD40 Ligand Sales by Country (2021-2032)
- 5.7.3 South America CD40 Ligand Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa CD40 Ligand Market Facts & Figures by Country
- 5.8.1 Middle East and Africa CD40 Ligand Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa CD40 Ligand Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa CD40 Ligand Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global CD40 Ligand Sales by Type (2021-2032)
- 6.1.1 Global CD40 Ligand Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global CD40 Ligand Sales Market Share by Type (2021-2032)
- 6.2 Global CD40 Ligand Revenue by Type (2021-2032)
- 6.2.1 Global CD40 Ligand Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global CD40 Ligand Revenue Market Share by Type (2021-2032)
- 6.3 Global CD40 Ligand Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global CD40 Ligand Sales by Application (2021-2032)
- 7.1.1 Global CD40 Ligand Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global CD40 Ligand Sales Market Share by Application (2021-2032)
- 7.2 Global CD40 Ligand Revenue by Application (2021-2032)
- 7.2.1 Global CD40 Ligand Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global CD40 Ligand Revenue Market Share by Application (2021-2032)
- 7.3 Global CD40 Ligand Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 CD40 Ligand Value Chain Analysis
- 8.1.1 CD40 Ligand Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 CD40 Ligand Production Mode & Process
- 8.2 CD40 Ligand Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 CD40 Ligand Distributors
- 8.2.3 CD40 Ligand Customers
9 Global CD40 Ligand Analyzing Market Dynamics
- 9.1 CD40 Ligand Industry Trends
- 9.2 CD40 Ligand Industry Drivers
- 9.3 CD40 Ligand Industry Opportunities and Challenges
- 9.4 CD40 Ligand Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst